CIBC Raises Theratechnologies (TH) Price Target to C$15.00
Separately, National Bank Financial reduced their price objective on Theratechnologies from C$9.75 to C$8.75 and set an outperform rating for the company in a research report on Tuesday, November 14th.
Shares of Theratechnologies (TSE TH) opened at C$9.94 on Wednesday. Theratechnologies has a 52-week low of C$4.91 and a 52-week high of C$10.05. The company has a market capitalization of $745.27, a P/E ratio of -39.76 and a beta of 0.52.
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.